Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it will
exhibit the breadth and promise of its cancer and infectious
disease immunotherapy, vaccine and DNA-based monoclonal antibody
(dMAb) pipeline in 10 presentations at the 19th Annual Meeting of
the American Society of Gene & Cell Therapy (ASGCT) held in
Washington, DC from May 4-7.
The ASGCT abstract review committee selected
Inovio’s presentation of its successful preclinical Ebola vaccine
development for one of only three presentations to be given at its
prestigious Presidential Symposium. In the selected abstract, out
of 768 submitted and accepted, the presented preclinical testing in
mice and non-human primates showed Inovio’s Ebola vaccine protected
100% of immunized animals from sickness and death following
exposure to a lethal dose of Ebola virus. Those results led
to a study of 75 healthy subjects which showed the vaccine was
safe, tolerable, and generated strong T cell and antibody responses
in human as well.
Inovio’s Ebola results will be offered on
Friday, May 6, at 2:50 p.m. in a presentation entitled: “479 - An
Optimized DNA Vaccine Formulation Protects Against Lethal Ebola
Makona Virus Challenge in Non-Human Primates and Elicits Robust
Immune Responses.”
Dr. J. Joseph Kim, President and CEO, said, “The
results we will present at the ASGCT global scientific forum
demonstrate the potential and breadth of the three pillars of
Inovio’s broad pipeline: Immunotherapies and vaccines against
cancers and challenging infectious diseases and our DNA-encoded
monoclonal antibodies (dMAbs), which we believe will offer clear
advantages over conventional monoclonal antibody technologies
including faster development, easier product manufacturing, and
more favorable pharmacokinetics.”
Inovio and its collaborators will present
clinical and preclinical data that supports its on-going trials
exploring the next generation of immunotherapies, vaccine and
monoclonal antibodies at the following times over the next two days
(link to abstracts):
19th Annual Meeting of the American
Society of Gene & Cell Therapy
May 5
264 - In Vivo DNA-Monoclonal Antibody (DMAb)
Gene Delivery Protects Against Lethal Bacterial and Viral
Challenges in Mice5:30 – 5:45 p.m.
428 - Generation of DNA Plasmid-Encoded
Neutralizing Monoclonal Antibodies In Vivo6:00 – 8:00 p.m.
433 - DNA Monoclonal Antibodies Target Influenza
Virus In Vivo6:00 – 8:00 p.m.
435 - Skin Delivery of a RSV Vaccine with
Surface Electroporation Provides Full Protection from Lower
Respiratory Disease in the Cotton Rat6:00 – 8:00 p.m.
436 - Developing a Synthetic DNA Vaccine for an
Emerging Pathogen – Middle East Respiratory Syndrome6:00 – 8:00
p.m.
440 - Extreme Polyvalency Induces Potent
Cross-Clade Cellular and Humoral Responses in Rabbits and Non-Human
Primates6:00 – 8:00 p.m.
401 - In Vivo Expression of Plasmid Encoded IgG
for PD-1 or LAG3 by Synthetic DNA as a New Tool for Cancer
Immunotherapy6:00 – 8:00 p.m.
May 6
479 - An Optimized DNA Vaccine Formulation
Protects Against Lethal Ebola Makona Virus Challenge in Non-Human
Primates and Elicits Robust Immune Responses2:50 – 3:10 p.m.
505 - VGX-3100 Drives Regression of HPV16/18
CIN2/3 and Robust Cellular Immune Responses in Blood and Cervical
Tissue in a Blinded, Randomized, Placebo-Controlled Phase 2B
Study4:00 – 4:15 p.m.
643 - Various Forms of CD40L Encoded as an
Immune Plasmid Adjuvant Generate Unique Anti-Cancer DNA Vaccine
Induced Responses6:00 – 8:00 p.m.
About the American Society of Gene &
Cell Therapy (ASGCT)
ASGCT is the primary professional membership
organization for gene and cell therapy. The Society's members are
scientists, physicians, patient advocates, and other professionals.
Its members work in a wide range of settings including
universities, hospitals, government agencies, foundations,
biotechnology and pharmaceutical companies. Its mission is to
advance knowledge, awareness, and education leading to the
discovery and clinical application of gene and cell therapies to
alleviate human disease.
About Inovio Pharmaceuticals,
Inc.
Inovio is taking immunotherapy to the next level
in the fight against cancer and infectious diseases. We are the
only immunotherapy company that has reported generating T cells in
vivo in high quantity that are fully functional and whose killing
capacity correlates with relevant clinical outcomes with a
favorable safety profile. With an expanding portfolio of immune
therapies, the company is advancing a growing preclinical and
clinical stage product pipeline. Partners and collaborators include
MedImmune, Roche, The Wistar Institute, University of Pennsylvania,
DARPA, GeneOne Life Science, Drexel University, NIH, HIV Vaccines
Trial Network, National Cancer Institute, U.S. Military HIV
Research Program, and University of Manitoba. For more information,
visit www.inovio.com.
This press release contains certain
forward-looking statements relating to our business, including our
plans to develop electroporation-based drug and gene delivery
technologies and DNA vaccines, our expectations regarding our
research and development programs and our capital resources. Actual
events or results may differ from the expectations set forth herein
as a result of a number of factors, including uncertainties
inherent in pre-clinical studies, clinical trials and product
development programs (including, but not limited to, the fact that
pre-clinical and clinical results referenced in this release may
not be indicative of results achievable in other trials or for
other indications, that the studies or trials may not be successful
or achieve the results desired, including safety and efficacy for
VGX-3100 and INO-3112, that pre-clinical studies and clinical
trials may not commence or be completed in the time periods
anticipated, that results from one study may not necessarily be
reflected or supported by the results of other similar studies and
that results from an animal study may not be indicative of results
achievable in human studies), the availability of funding to
support continuing research and studies in an effort to prove
safety and efficacy of electroporation technology as a delivery
mechanism or develop viable DNA vaccines, our ability to support
our broad pipeline of SynCon® active immune therapy and vaccine
products, our ability to advance our portfolio of immune-oncology
products independently, the ability of our collaborators to attain
development and commercial milestones for products we license and
product sales that will enable us to receive future payments and
royalties, the adequacy of our capital resources, the availability
or potential availability of alternative therapies or treatments
for the conditions targeted by the company or its collaborators,
including alternatives that may be more efficacious or
cost-effective than any therapy or treatment that the company and
its collaborators hope to develop, our ability to enter into
partnerships in conjunction with our research and development
programs, evaluation of potential opportunities, issues involving
product liability, issues involving patents and whether they or
licenses to them will provide the company with meaningful
protection from others using the covered technologies, whether such
proprietary rights are enforceable or defensible or infringe or
allegedly infringe on rights of others or can withstand claims of
invalidity and whether the company can finance or devote other
significant resources that may be necessary to prosecute, protect
or defend them, the level of corporate expenditures, assessments of
the company's technology by potential corporate or other partners
or collaborators, capital market conditions, the impact of
government healthcare proposals and other factors set forth in our
Annual Report on Form 10-K for the year ended December 31, 2015,
and other regulatory filings from time to time. There can be no
assurance that any product in Inovio's pipeline will be
successfully developed or manufactured, that final results of
clinical studies will be supportive of regulatory approvals
required to market licensed products, or that any of the
forward-looking information provided herein will be proven
accurate.
CONTACTS:
Investors: Bernie Hertel, Inovio Pharmaceuticals, 858-410-3101, bhertel@inovio.com
Media: Jeff Richardson, Inovio Pharmaceuticals, 267-440-4211, jrichardson@inovio.com
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Aug 2024 to Sep 2024
Inovio Pharmaceuticals (NASDAQ:INO)
Historical Stock Chart
From Sep 2023 to Sep 2024